24/7 Market News Snapshot 21 January, 2025 – GlucoTrack, Inc. Common Stock (NASDAQ:GCTK)

January 21, 2025

DENVER, Colo., 21 January, 2025 (247marketnews.com) – (Nasdaq:GCTK) are discussed in this article.
GlucoTrack, Inc. (Nasdaq:GCTK), a leader in medical technology focused on advancing diabetes care, has recently experienced a notable surge in pre-market trading, with shares skyrocketing to $0.109, reflecting an increase of over 28% from the previous close. This momentum, characterized by a trading volume of 97.23 million shares, signifies heightened market interest in the company’s innovative diabetes management solutions. The bullish trend, driven by investor enthusiasm, underscores the potential for future growth as momentum builds.

Compounding this positive trajectory, GlucoTrack has achieved significant recognition by securing ISO 13485:2016 certification from the British Standards Institute (BSI). This certification underscores the company’s unwavering commitment to maintaining high standards in quality management throughout the design and development of its groundbreaking products. Dr. Paul V. Goode, CEO of GlucoTrack, highlighted this achievement as a critical milestone in the organization’s mission to deliver high-quality healthcare solutions that align with industry demands.

The certification process entailed rigorous assessments confirming that GlucoTrack’s quality management system meets the stringent requirements of the ISO 13485:2016 standard, a key benchmark for ensuring the safety and efficacy of medical devices. This advancement positions GlucoTrack favorably as the U.S. Food and Drug Administration’s recent final rule harmonizes regulatory practices with international standards, enhancing the company’s market readiness and compliance.

As GlucoTrack progresses in the development of its revolutionary Continuous Blood Glucose Monitor (CBGM), designed for long-term use with minimal calibration and no wearable components, the company is poised for significant innovation. This achievement further solidifies GlucoTrack’s dedication to improving the quality of life for diabetes patients globally. With the recent gains and strategic advancements, stakeholders can anticipate exciting developments in the company’s future endeavors.

Related news for (GCTK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.